Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Political Science Scholar with Personal
September 10, 2007
- NEW PRODUCTS／Daiichi Sankyo: Fentanyl for Infants
September 10, 2007
- RIKEN Kobe Institute to Develop
September 10, 2007
- Takeshi Erikawa Appointed
September 10, 2007
- Korosho to Train Senior CRCs, Data Managers, IRB Members
September 10, 2007
- Korosho to Demand \22,160.4 Bil., Up 3.2%, in FY2008
September 10, 2007
- Korosho to Standardize Forms for Clinical Trial Documents
September 10, 2007
- Japan's 1st Drug for ADHD Recommended for Approval
September 10, 2007
- R&D NEWS IN BRIEF
September 10, 2007
- Korosho to Create "Healthcare Clusters" to Promote Drug Discovery
September 10, 2007
- Our Generics Had Economic Effects of \58.6 Bil. in 2006: Taiyo Yakuhin
September 10, 2007
- JMA Proposes Same Prices for Original Drugs and Generics
September 10, 2007
- Major Pharmas Tie Up with Generic Firms: Seminar
September 10, 2007
- REGULATORY NEWS IN BRIEF
September 10, 2007
- JGPRG to Designate Oct. as "Generic Drug Promotion Month"
September 10, 2007
- NBI to Go on Offensive in the Market for ARBs with 1,000 MRs
September 10, 2007
- GENERICS NEWS IN BRIEF
September 10, 2007
- Leiden Bio Science Park Is Ideal Gateway to Europe: F. van As of Leiden City
September 10, 2007
- Reimbursement Begins for 4 Lab Tests
September 10, 2007
- Korosho Asks Makers to Present Criteria for Allowances ASAP after Notification of New NHI Prices
September 10, 2007
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…